KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Average (2016 - 2025)

Alnylam Pharmaceuticals' Equity Average history spans 16 years, with the latest figure at $511.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 928.81% year-over-year to $511.5 million; the TTM value through Dec 2025 reached $511.5 million, up 928.81%, while the annual FY2025 figure was $428.1 million, 657.62% up from the prior year.
  • Equity Average reached $511.5 million in Q4 2025 per ALNY's latest filing, up from $242.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $971.2 million in Q1 2021 to a low of -$333.7 million in Q2 2023.
  • Average Equity Average over 5 years is $190.0 million, with a median of $72.7 million recorded in 2022.
  • Peak YoY movement for Equity Average: tumbled 629.51% in 2023, then soared 1554.27% in 2025.
  • A 5-year view of Equity Average shows it stood at $672.0 million in 2021, then tumbled by 116.8% to -$112.9 million in 2022, then crashed by 71.13% to -$193.3 million in 2023, then surged by 125.73% to $49.7 million in 2024, then surged by 928.81% to $511.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Equity Average are $511.5 million (Q4 2025), $242.2 million (Q3 2025), and $183.0 million (Q2 2025).